Table 1.
Demographic and clinical characteristics of the study sample by antipsychotic medication
| All drugs n (%) (N=2138) |
Aripiprazole n (%) (N=214) |
Olanzapine n (%) (N=539) |
Quetiapine n (%) (N=394) |
Risperidone n (%) (N=690) |
Ziprasidone n (%) (N=139) |
Chlorpromazine n (%) (N=47) |
Haloperidol n (%) (N=115) |
|
|---|---|---|---|---|---|---|---|---|
| Age (years) | ||||||||
| 19–34 | 118 ( 5.6) | 19 ( 9.0) | 27 ( 5.0) | 16 ( 4.1) | 42 ( 6.1) | 13 ( 9.4) | 0 (0.0) | 1 ( 0.9) |
| 35–49 | 773 (36.4) | 89 (42.0) | 195 (36.3) | 161 (41.2) | 220 (32.1) | 61 (44.2) | 12 (25.5) | 35 (30.4) |
| 50–64 | 975 (45.9) | 91 (42.9) | 243 (45.3) | 172 (44.0) | 336 (49.0) | 50 (36.2) | 25 (53.2) | 58 (50.4) |
| 65+ | 260 (12.2) | 13 ( 6.1) | 72 (13.4) | 42 (10.7) | 88 (12.8) | 14 (10.1) | 10 (21.3) | 21 (18.3) |
| Race | ||||||||
| White | 606 (28.3) | 72 (33.6) | 152 (28.2) | 124 (31.5) | 163 (23.6) | 50 (36.0) | 12 (25.5) | 33 (28.7) |
| Non-White | 1005 (47.0) | 75 (35.0) | 268 (49.7) | 178 (45.2) | 361 (52.3) | 46 (33.1) | 27 (57.4) | 50 (43.5) |
| Missing | 527 (24.6) | 67 (31.3) | 119 (22.1) | 92 (23.4) | 166 (24.1) | 43 (30.9) | 8 (17.0) | 32 (27.8) |
| Male | 1979 (92.6) | 193 (90.2) | 512 (95.0) | 358 (90.9) | 643 (93.2) | 118 (84.9) | 45 (95.7) | 110 (95.7) |
| Homeless | 251 (11.7) | 19 ( 8.9) | 57 (10.6) | 56 (14.2) | 91 (13.2) | 12 ( 8.6) | 4 ( 8.5) | 12 (10.4) |
| Substance use disorder | 539 (25.2) | 43 (20.1) | 138 (25.6) | 126 (32.0) | 176 (25.5) | 27 (19.4) | 5 (10.6) | 24 (20.9) |
| Service-connected disability rating >50% | 953 (44.8) | 109 (51.2) | 218 (40.5) | 162 (41.3) | 308 (44.8) | 65 (47.8) | 30 (63.8) | 61 (53.0) |
| Any mental health/substance abuse hospitalization in prior 3 months | 373 (17.4) | 27 (12.6) | 104 (19.3) | 63 (16.0) | 114 (16.5) | 27 (19.4) | 6 (12.8) | 32 (27.8) |
| Any mental health/substance abuse outpatient visit in prior 3 months | 1616 (75.6) | 176 (82.2) | 405 (75.1) | 314 (79.7) | 500 (72.5) | 108 (77.7) | 33 (70.2) | 80 (69.6) |
| Prescribed a different antipsychotic at the time of discontinuation of index antipsychotic | 338 (15.8) | 54 (25.2) | 76 (14.1) | 72 (18.3) | 69 (10.0) | 30 (21.6) | 9 (19.1) | 28 (24.3) |